RESEARCH AND DEVELOPMENT
Know which R&D bets are paying off, while they’re still bets
Planview is the platform for R&D execution and outcomes. It sits above the engineering and product systems where the work happens, bringing R&D investments, capacity, cross-discipline dependencies, and outcomes into one connected model. So R&D leaders can pivot before the window closes, get the right products to market faster, and prove what every R&D bet delivered.
Watch Demo Pivot in time. See how.Trusted by 3,000+ of the world’s leading enterprises
Enterprise R&D has a pivot problem
The pipeline runs on bets, and you find out which paid off after launch — too late to kill, double down, or redirect. Competitive moves, supply shocks, and regulatory shifts move faster than your funding cycles. Compliance and growth compete for the same capacity, with no portfolio model to defend the trade-off.
The Planview Platform was built to fix this. It sits above the PLM, ERP, and engineering systems where the work happens, connecting that execution to strategy, capacity, and returns in one continuous model. It gives you foresight on which bets are pulling ahead, not hindsight after launch
Pivot in time. Get the right products to market faster. Prove what each bet delivered.
Erfolgsgeschichten
How three R&D leaders made pipeline ROI defensible
95% reduction in manual reporting
Thermo Fisher Scientific implemented Planview as the standardized single source of truth across the vast majority of the R&D organization.
“By having a significant portion of the company using Planview, the opportunities for identifying gaps have accelerated. This enables us to solve challenges faster and also creates opportunity.”
Senior Portfolio and Program Management Analyst, Thermo Fisher Scientific
Read Customer Story
Six signs you have a pivot problem
-
1
The CFO challenges R&D as a percent of revenue and the defense is reputation, not numbers.
-
2
Competitive shifts, supply shocks, and regulatory changes move faster than funding decisions respond.
-
3
AI is accelerating design and engineering work with no view of strategic priorities or trade-offs.
-
4
Compliance work consumes capacity meant for growth bets, with no portfolio view to defend the trade-off.
-
5
Launch dates slip into the next fiscal year because the pivot came too late.
-
6
Pipeline credibility erodes each funding cycle because the last cycle can’t be proven.
The cost of finding out too late is the variance no one budgets for — and the hardest to defend. The on-demand demo shows what mid-flight proof looks like.
Anerkennung durch Analyseunternehmen
The analysts who advise your board name us a Leader, year after year
über 3.000
Kunden auf der ganzen Welt
3.1M
Benutzer auf der Planview Plattform
45%
des Fortune 100 Konzerns Planview
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Peer Reviews
ON-DEMAND-DEMO
Watch mid-flight R&D portfolio management in action
See how Planview gives R&D leaders real-time foresight on which pipeline bets are pulling ahead — so you can pivot, kill, or double down before the launch window closes.
Demo ansehen
How Planview helps
Your Challenge
- Pipeline returns you can’t prove
- Pivot window closes before you see it
- Compliance crowding out growth
- AI accelerating without portfolio context
- R&D reacting, rarely steering
Problem
You’re betting millions or billions on the pipeline and can’t answer, until products are in-market, whether the bets paid off.
What it costs you
- R&D budgets keep flowing into bets the CEO and board can’t see the return on.
- Pipeline credibility erodes, and every funding ask gets harder.
- The CFO challenges R&D as a percent of revenue and the defense is reputation, not numbers.
Planview delivers
- Investment-to-outcome tracking: Trace pipeline spend to in-market outcomes, with mid-flight signal on where each bet is converging.
- Demand intake standardization: Capture NPI, sustaining, and compliance work in one model so the pipeline narrative reflects total engineering load.
- Tool stack coherence above PLM, ERP, and engineering systems: One enterprise view of investments and capacity, without replacing the engineering toolchain.
Resources for R&D leaders: research, reports, webinars and guides
Leitfaden abrufen
Der unverzichtbare Kaufleitfaden für Produktportfoliomanagement-Lösungen
Whitepaper herunterladen
Effektive Produktentwicklung: Erkenntnisse aus der Analyse der Top 3 Störungen
Whitepaper herunterladen
Der Weg zu einer nachhaltigen Produktentwicklungsstrategie
Webinar ansehen
Anpassen in der Ungewissheit: Best Practices für effektives Produktportfolio-Management
Webinar ansehen
Anpassung in einer von Unsicherheit geprägten Welt
Download the solution brief
Planview Produktportfoliomanagement
Planview in Aktion
Sehen Sie sich die On-Demand-Demos an und erfahren Sie, wie Planview Ihnen hilft, schneller Entscheidungen zu treffen, als Einheit zu handeln und Ergebnisse zu beweisen.
Alle Demos durchsuchen
Sind Sie bereit, tiefer zu gehen?
Sagen Sie uns, wo Ihre Portfolioentscheidungen scheitern. Wir zeigen Ihnen genau, wo Planview eingesetzt werden kann und was es in der Regel für Organisationen Ihrer Größenordnung leistet.
KontaktThe right solution for every type of strategic bet
See how Planview supports your function
Produktentwicklung
Prioritize the right bets, coordinate engineering, supply, and regulatory on one plan, and get the right products to market faster — with every R&D investment tied to the revenue it returned.
Strategisches Portfoliomanagement
Reprioritize investment at the speed the market moves, keep capacity and AI aligned to approved strategy, and prove the outcome of every bet at the portfolio level.
Bereitstellung von Softwareprodukten
Re-sequence software investment when strategy shifts, pull every team and toolchain onto one delivery signal, and prove what engineering delivered, including the AI bets.
Häufige Fragen
The structure usually isn’t the problem. Portfolio review boards, Stage-Gate committees, quarterly investment reviews, monthly program reviews — most R&D organizations already have them. What breaks is the data underneath. Decisions get made in the room, then teams spend the next two weeks reconciling what was approved against what’s actually being delivered across engineering, supply, and regulatory.
Planview gives the portfolio review board, Stage-Gate sponsors, and executive R&D leadership one connected model of pipeline investments, capacity, and outcomes — pre-populated to the review, not assembled the week before. Gate decisions move from escalation to routine, the line of sight set at funding stays intact through launch, and the executive team sees what the engineering teams are running on.
These are judgment calls, and they should stay that way. What slows them down is preparing the evidence: pulling outcome trajectory, capacity consumed, and the opportunity cost of redeployed engineering talent together in one defensible view, fast enough to act on mid-flight.
Planview helps R&D leaders narrow the pipeline and keep it sharp. Thermo Fisher Scientific standardized R&D portfolio data across product development programs and cut manual reporting by up to 95%, so leadership evaluates investments faster on real-time data.
Mid-flight visibility comes from one live model, not a post-mortem rebuild. When pipeline progress, capacity, financials, and outcome data feed a single source, leadership pulls the portfolio view the morning of the review and the numbers match what engineering, regulatory, and supply are running on, with leading indicators of attainment alongside lagging results so the conversation moves from explaining variance to deciding what to do.
Planview provides that live model. NuVasive improved visibility across complex medical device development, identifying issues earlier and reducing gate-to-gate cycle time, so leadership reviews the portfolio in flight, not after launch.
Systematic adaptation depends on a model that sits above PLM, ERP, and the engineering toolchain, not another system that replaces them. Teams keep working where they work, while a connected layer of strategy, funding, capacity, and outcomes reads from those systems, so replanning happens against live data instead of in crisis mode.
Planview provides that layer, with 60+ live integrations into PLM (Teamcenter, Windchill, ENOVIA), ERP (SAP, Oracle), engineering tools, and project systems. NIO used Planview Hub to connect R&D processes across suppliers, business data, and engineering tools without replacing them, automating compliance traceability and shortening project delivery times.
Governing AI in R&D means treating agents like any other resource: with a defined scope of authority, attributed cost, and accountability to a human, plus the IP, compliance, and safety exposure that R&D uniquely carries. Agent compute and token spend has to be attributed to the pipeline program it supports, and every autonomous action needs an owner.
Planview’s agent resource management governs AI agents the same way it governs human R&D capacity, with full cost attributed to a specific pipeline program and every action accountable to a human decision-maker. The same model runs substitution scenarios across the portfolio to forecast the ROI of different human-to-agent mixes before commit.
Gartner forecasts that 40% of enterprise applications will use task-specific AI agents by end of 2026. For R&D, governing the blended workforce — and the IP, compliance, and safety exposure that comes with it — is the new portfolio job.